Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling

Hilary P. Glazer  
*Washington University School of Medicine in St. Louis*

Robert M. Osipov  
*Harvard University*

Richard T. Clements  
*Harvard University*

Frank W. Sellke  
*Harvard University*

Cesario Bianchi  
*Harvard University*

---

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

---

**Recommended Citation**

[https://digitalcommons.wustl.edu/open_access_pubs/3014](https://digitalcommons.wustl.edu/open_access_pubs/3014)

---

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Hypercholesterolemia is associated with hyperactive cardiac mTORC1 and mTORC2 signaling

Hilary P. Glazer,1,2 Robert M. Osipov,1 Richard T. Clements,1 Frank W. Sellke1,3 and Cesario Bianchi1,*

1Division of Cardiothoracic Surgery Research; Beth Israel Deaconess Medical Center & Harvard Medical School; Boston, MA USA; 2Washington University in St. Louis School of Medicine; St. Louis, MO USA; 3Alpert Medical School of Brown University; Providence, RI USA

Abbreviations: mTOR, mammalian target of rapamycin; HC, hypercholesterolemic; NC, normocholesterolemic; S6K1, S6 kinase 1; 4EBP1, eukaryotic translation initiation factor 4E binding protein 1; S6, ribosomal protein S6; PKCα, protein kinase C alpha; I/R, ischemia-reperfusion; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; mLST8, G protein β-subunit-like protein; PRAS40, proline-rich Akt substrate of 40 kDa; AMPK, AMP-activated protein kinase; Rheb, ras homolog enriched in brain; REDD1, regulated in development and DNA damage 1; HIF-1 responsive protein; SERCA2 ATPase, sarcoplasmic/endoplasmic reticulum calcium ATPase 2; LC3B, microtubule-associated protein 1 light chain 3B; HIF-1α, hypoxia-inducible factor 1α; MAP, mean arterial pressure

Key words: hyperlipidemia, nutrition, rapamycin, hypertrophy, ischemia, oxidative stress, autophagy, senescence, mitochondria, localization

Nutritional excess and hyperlipidemia increase the heart’s susceptibility to ischemic injury. Mammalian target of rapamycin (mTOR) controls the cellular response to nutritional status and may play a role in ischemic injury. To explore the effect of hypercholesterolemia on cardiac mTOR signaling, we assessed mTOR signaling in hypercholesterolemic swine (HC) that are also susceptible to increased cardiac ischemia-reperfusion injury. Yucatan pigs were fed a high-fat/high-cholesterol diet for 4 weeks to induce hypercholesterolemia, and mTOR signaling was measured by immunoblotting and immunofluorescence in the non-ischemic left ventricular area. Total myocardial mTOR and raptor levels were markedly increased in the HC group compared to the normocholesterolemic group, and directly correlated with serum cholesterol levels. mTOR exhibited intense perinuclear staining in myocytes only in the HC group. Hypercholesterolemia was associated with hyperactive signaling upstream and downstream of both mTOR complexes, including myocardial Akt, S6K1, 4EBP1, S6 and PKC-alpha, increased levels of cardiac hypertrophy markers, and a trend toward lower levels of myocardial autophagy. Hypercholesterolemia can now be added to the growing list of conditions associated with aberrant mTOR signaling. Hypercholesterolemia produces a unique profile of alterations in cardiac mTOR signaling, which is a potential target in cardiac diseases associated with hypercholesterolemia and nutritional excess.

*Correspondence to: Cesario Bianchi; Beth Israel Deaconess Medical Center; 330 Brookline Ave., Dana 805C; Boston, MA 02215 USA; Tel.: 617.667.0342; Fax: 617.975.5562; Email: cbianchi@bidmc.harvard.edu

Submitted: 03/12/09; Accepted: 04/03/09
Previously published online as a Cell Cycle E-publication: http://www.landesbioscience.com/journals/cc/article/8619

Introduction

Hyperlipidemia is one of the most common risk factors for coronary heart disease, and is associated with increased morbidity and mortality from cardiac events and procedures.1,2 Major studies have shown that diet, particularly those high in saturated fat, also plays a fundamental role in cardiovascular risk.3 We recently showed a 45% greater myocardial infarct after ischemia-reperfusion (I/R) in hypercholesterolemic pigs fed a high-fat/high-cholesterol diet for four weeks,4 which is much shorter than the time needed to produce atherosclerosis.5 Fortunately, mortality from cardiovascular disease has declined drastically in the last 50 years due to decreases in serum cholesterol and the modification of other risk factors. Experts believe, however, that this trend has slowed due to unhealthy eating patterns in the majority of the US population, specifically with respect to the overconsumption of energy-rich foods.6

Mammalian target of rapamycin (mTOR) plays a central role in integrating the cell’s response to nutritional status, including intracellular ATP, glucose and amino acid levels.7 Hyperactivation of mTOR has been shown to increase most organs’ sensitivity to oxidative stress.8 The etiology of many diseases associated with aging has been attributed to increased oxidative stress and more recently, to hyperactivation of mTOR through multiple mechanisms including nutrient excess.9 mTOR exists in mTOR complex 1 (mTORC1) with raptor and mTOR complex 2 (mTORC2) with rictor. mTORC1 is activated by Akt and inhibited by AMPK, and promotes protein synthesis and leads to cardiac hypertrophy through its activation of S6K1 and S6, and inhibition of 4EBP1 and autophagy. mTORC2 activates Akt and PKCα, and may also contribute to cardiac hypertrophy.10 While some studies have shown that prior activation of Akt or S6K1 are important for cell survival after I/R,11,12 others have suggested that rapamycin
induces a metabolic state that protects cardiomyocytes from I/R injury.\textsuperscript{10,13,14}

The effect of hypercholesterolemia on mTOR signaling has not been studied. We examined mTORC1 and 2 signaling in pigs fed a high cholesterol diet for 4 weeks, in order to study the effect of hypercholesterolemia on myocardial signaling independent of secondary effects related to atherosclerosis and underlying ischemia. Since hypercholesterolemia is likely produced through the complex interplay of dietary and genetic factors, a large animal model was used that may be more applicable to patients than traditional rodent models.\textsuperscript{15} Here we describe that hyperactive myocardial mTOR signaling is present in early hypercholesterolemia, and implicate mTOR complex 1 and 2 signaling in altering myocardial metabolism and susceptibility to ischemic injury.

**Results**

**Biochemical parameters and body weight.** The high-fat/high-cholesterol diet induced significant elevations in serum total cholesterol, LDL and HDL in the HC group (p < 0.01 for all; Table 1). Triglycerides tended to be slightly higher in the HC group (p = 0.051), and body weight was similar between groups. Some pigs in the HC group displayed elevations in serum glucose and insulin levels, but the differences were not significant, and HOMA-IR, a measure of insulin resistance,\textsuperscript{16} tended to be higher in the HC group (data not shown).

**mTORC1 and 2 components.** mTOR levels were increased by about 3-fold in the HC group (p < 0.01), and raptor levels were increased by more than 5-fold in the HC group (p < 0.01). In contrast, levels of rictor and mLST8 were not significantly different between groups (p = 0.4 and p = 0.8, respectively; Fig. 1). mTOR and raptor levels exhibited strong direct correlations with serum total cholesterol and HDL levels (Table 2; for correlation plots see Suppl. Fig. 1). mTOR and raptor levels exhibited modest and strong direct correlations with serum LDL, respectively. There was no correlation between mTOR and raptor levels and triglycerides or body weight. mTOR levels also showed a modest correlation with insulin levels and HOMA-IR measurements, while raptor levels showed no correlation with any measures of insulin resistance (data not shown).

**Signaling upstream of mTORC1.** The phosphorylation of Akt at Thr308, as measured by the ratio of phospho-to-total levels of the protein, tended to be higher in HC group (p = 0.052; Fig. 2). PRAS40 phosphorylation at Thr246 and mTOR phosphorylation at Ser2448 were higher in the HC group (p < 0.01 and p < 0.01, respectively). Total levels of Akt did not change (p = 0.6), while total levels of PRAS40 tended to be slightly lower in the HC group (p = 0.14). AMPKα phosphorylation at Thr172 was significantly lower in the HC group (p < 0.01; Fig. 3), while levels of total AMPKα were slightly higher in the HC group (p = 0.19). Levels of Rheb were lower in the HC group (p < 0.05), while there was no difference in REDD1 levels between the groups (p = 0.3).

**mTORC1 activity.** The phosphorylation of 4EBP1 at Thr37/46 and S6K1 at Thr389 was increased by more than 2-fold in the HC group (p < 0.01 and p < 0.05, respectively; Fig. 4), and S6 phosphorylation at Ser240/244 was significantly higher in the HC group (p < 0.05). However, total levels of 4EBP1, S6K1 and S6 were unchanged (p = 0.4, 0.6 and 1, respectively).

**mTORC2 activity.** The phosphorylation of Akt at Ser473 was significantly higher in the HC group (p < 0.05; Fig. 5). As measured by a pan-PKC antibody with reactivity to Ser657 of PKCα, the phosphorylation of a PKC isoform at the same molecular weight as PKCα was increased by more than 2-fold in the HC group (p < 0.01), and levels of PKCα were also higher in the HC group (p < 0.01).

**Immunolocalization of mTOR.** Immunofluorescence studies showed that mTOR was highly expressed in myocytes (Fig. 6).

### Table 1 Lipid profile and body weight

<table>
<thead>
<tr>
<th></th>
<th>NC</th>
<th>HC</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chol (mmol/L)</td>
<td>1.61 ± 0.27</td>
<td>13.8 ± 1.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>0.53 ± 0.05</td>
<td>5.46 ± 0.74</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>0.53 ± 0.06</td>
<td>1.81 ± 0.11</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>0.30 ± 0.14</td>
<td>0.33 ± 0.03</td>
<td>0.051</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td>22.4 ± 1.5</td>
<td>21.4 ± 0.9</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Yucatan pigs were fed a normocholesterolemic (NC, n=6) or a high-fat/high-cholesterol diet (HC, n=7) for 4 weeks. Serum total cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and body weight were measured. Values are expressed as mean ± SEM, with corresponding p values.
Yucatan pigs were fed a normal or high-fat/high-cholesterol diet for 4 weeks. Left ventricular mTOR and raptor levels were measured by immunoblotting. Serum total cholesterol (Chol), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG) and body weight were also measured. Correlation (r) with corresponding p values are shown. For correlation plots, see Supplemental Figure 1.

Table 2: Correlation of lipid profile and body weight with cardiac mTOR and raptor levels

<table>
<thead>
<tr>
<th></th>
<th>mTOR</th>
<th></th>
<th>raptor</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chol</td>
<td>0.57</td>
<td>&lt;0.05</td>
<td>0.81</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LDL</td>
<td>0.53</td>
<td>0.06</td>
<td>0.77</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HDL</td>
<td>0.72</td>
<td>&lt;0.01</td>
<td>0.81</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TG</td>
<td>0.24</td>
<td>0.41</td>
<td>0.33</td>
<td>0.27</td>
</tr>
<tr>
<td>Body Weight</td>
<td>0.08</td>
<td>0.79</td>
<td>0.05</td>
<td>0.86</td>
</tr>
</tbody>
</table>

Figure 2. Hypercholesterolemia is associated with increased in cardiac Akt/mTOR signaling. Representative western blots for phospho-Akt (Thr308), phospho-PRAS40 (Thr246), phospho-mTOR (Ser2448), and total levels of Akt, PRAS40 and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of the data. The phospho-mTOR blot corresponds to the total mTOR blot shown in Figure 1. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01 versus control.

and could not be detected in other cardiac cell types, such as the vascular endothelium or smooth muscle. Of the 3 animals examined from each group, all of the HC animals exhibited mTOR staining in a punctate perinuclear distribution, whereas staining for mTOR in the ND animals was diffusely cytoplasmic when detectable. A similar cellular expression and distribution was seen for phospho-S6K1 (data not shown). To confirm the specificity of the mTOR antibody, we incubated the mTOR antibody with a blocking peptide, and this eliminated mTOR staining (Suppl. Fig. 2A). mTOR did not co-localize in the HC group with SERCA2 ATPase, a marker for the sarcoplasmic reticulum/endoplasmic reticulum (Suppl. Fig. 2B).

Cardiac hypertrophy and autophagy. Total levels of β-actin, troponin I, troponin T and SERCA2 ATPase were significantly increased in the HC group (p < 0.05 for all; Fig. 7), while levels of α-tubulin did not change (p = 0.7). The ratio of LC3B II/I also tended to be lower in the HC group (p = 0.08).

Correlation between biochemical parameters and mTORC1 and 2 signaling. The ratio of phospho-to-total mTOR, 4EBP1, Akt (Ser473) and total Rheb, PKCα, and SERCA2 ATPase directly correlated with serum total cholesterol and LDL levels (See Suppl. Table 1). The ratio of phospho-to-total AMPK inversely correlated with serum total cholesterol, LDL and HDL. None of the measured proteins or phosphorylated proteins exhibited a correlation with triglycerides or body weight, except total PKCα and troponin T, which directly correlated with triglycerides (Suppl. Table 1).

Discussion

Hypercholesterolemia is a major risk factor for coronary artery disease, myocardial infarction and adverse outcomes after ischemic events.1 It is also associated with cardiac hypertrophy.17 We demonstrate that early hypercholesterolemia in pigs increased total levels of mTOR and raptor and activated mTORC1 signaling. We show that mTORC2 signaling was activated since Akt and PKCα signaling was increased. The hypercholesterolemic pigs also showed higher levels of cardiac hypertrophy markers and a trend toward inhibition of autophagy in the myocardium. These findings carry important implications for the role of mTOR in altering cardiac metabolism in hypercholesterolemia, and may influence the heart’s response to ischemia.

Hypercholesterolemia activated mTORC1 through several mechanisms. Total levels of mTOR and raptor were increased and directly correlated with serum cholesterol, indicating that may be novel sensors to cholesterol levels. This occurred through an as-yet-undefined mechanism since levels of FOXO1 and 4EBP1, the only molecules known to regulate mTOR and raptor expression,18 were not changed (for FOXO1, see Suppl. Fig. 3A). In addition, Akt and AMPK were upstream mediators leading to activation of mTORC1. Akt was more phosphorylated on Thr308 and Ser473 in the HC group, and the mTORC1 inhibitor PRAS40 was more phosphorylated on Thr246, indicating that Akt contributed to mTOR activation via PRAS40 inhibition.19 The higher Ser2448 phosphorylation of mTOR also indicated that mTORC1 was more activated by Akt in the HC group, although S6K1 may also phosphorylate this site.20 AMPK, a key negative regulator of mTORC1,7 was less active (less phosphorylated on Thr172) in the HC group. Akt is sequentially activated, first by the phosphorylation of Thr308 by PDK1 through PI3K signaling, and then fully activated by mTORC2’s phosphorylation of Ser473.21 AMPK was likely inhibited by the high intracellular energy status in the HC group, since fatty acids are a principal source of energy to cardiomyocytes,22 and AMPK is inhibited by a high intracellular ATP/AMP ratio.23

1740 Cell Cycle 2009; Vol. 8 Issue 11
Hypercholesterolemia activates cardiac mTOR signaling

Other upstream modulators of mTORC1 activity were also altered in hypercholesterolemia, including Rheb, another nutrient-stimulated activator of mTORC1, which was decreased in the HC group. We also measured REDD1, which has been shown to be induced by oxidative stress, but it showed no change in the HC group, even though hypercholesterolemia is associated with chronic oxidative stress. However, the major downstream targets of mTORC1, 4EBP1 and S6K1, were hyperphosphorylated in the HC group, indicating that mTORC1 was activated in the HC group, likely due to both overexpression of mTOR and raptor as well as stimulation of upstream signaling, including Akt and AMPK. These sites are classic measures of mTORC1 activity. We also observed intense punctate perinuclear staining for mTOR in the HC group compared to diffuse cytoplasmic staining when detectable in the ND group. This is consistent with a similar shift in mTOR staining observed in human cells in vitro when mTORC1 was stimulated with amino acids, further suggesting that mTORC1 was activated in our model. Combined with the phosphorylation of Akt on Ser473 and PKCα on Ser657 were increased in the HC group. These residues are the main sites phosphorylated by mTORC2, and total levels of PKCα were higher in the HC group. The activity of mTORC2 may have been increased by the higher levels of mTOR in hypercholesterolemia, or still unknown upstream mediators. The major substrates of mTORC2 are Akt, which further activates mTORC1, and PKCα, which affects microvascular function and cardiac contractility.

Hypercholesterolemia activates myocardial mTORC2. Total levels of rictor, a key component of mTORC2, and mLST8, a component common to both complexes, were not altered in hypercholesterolemia. However, the phosphorylation of Akt on Ser473 and PKCα on Ser657 were increased in the HC group. These residues are the main sites phosphorylated by mTORC2, and mTORC2 also increases the stability of PKCα, and total levels of PKCα were higher in the HC group. The activity of mTORC2 may have been increased by the higher levels of mTOR in hypercholesterolemia, or still unknown upstream mediators.

We showed that hypercholesterolemia also activated myocardial mTORC2. Total levels of rictor, a key component of mTORC2, and mLST8, a component common to both complexes, were not altered in hypercholesterolemia. However, the phosphorylation of Akt on Ser473 and PKCα on Ser657 were increased in the HC group. These residues are the main sites phosphorylated by mTORC2, and mTORC2 also increases the stability of PKCα, and total levels of PKCα were higher in the HC group. The activity of mTORC2 may have been increased by the higher levels of mTOR in hypercholesterolemia, or still unknown upstream mediators.

The major substrates of mTORC2 are Akt, which further activates mTORC1, and PKCα, which affects microvascular function and cardiac contractility.

Hypercholesterolemia and diets high in saturated fat are independent risk factors for the development of left ventricular hypertrophy, which heavily influences morbidity and mortality from cardiovascular disease. The HC pigs displayed increased markers of cardiac hypertrophy, which is significant in light of the changes observed in mTOR signaling, mTORC1 regulates the development of cardiac hypertrophy, primarily via promotion of protein synthesis in myocytes. We observed enhanced phosphorylation of the ribosomal protein S6 in the HC group, and when coupled with the increased phosphorylation of 4EBP1, a translational inhibitor in its nonphosphorylated form, this...
Hypercholesterolemia activates cardiac mTOR signaling

![Figure 5. Hypercholesterolemia is associated with increased phosphorylation of mTORC2 targets, and an increase in PKCα levels in the myocardium. Representative western blots for phospho-Akt (Ser473), phospho-PKCα (α, Ser 657), total PKCα, and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of the data. For total levels of Akt corresponding to the phospho-Akt (Ser473) blot, see Figure 2. The phospho-PKC antibody was a phospho-pan PKC antibody with reactivity to PKCα when phosphorylated at Ser657. This is the thicker bottom band which overlapped with total PKCα. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01 versus control.](image)

Figure 5. Hypercholesterolemia is associated with increased phosphorylation of mTORC2 targets, and an increase in PKCα levels in the myocardium. Representative western blots for phospho-Akt (Ser473), phospho-PKCα (α, Ser 657), total PKCα, and α-tubulin in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of the data. For total levels of Akt corresponding to the phospho-Akt (Ser473) blot, see Figure 2. The phospho-PKC antibody was a phospho-pan PKC antibody with reactivity to PKCα when phosphorylated at Ser657. This is the thicker bottom band which overlapped with total PKCα. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S staining. Phosphorylation is presented as the phospho-to-total (p/t) ratio of the protein. Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01 versus control.

indicates a trend toward increased protein synthesis in the hypercholesterolemic myocardium. mTORC2 also plays a role in cardiac hypertrophy, since it controls the actin cytoskeleton and activates Akt and PKCα, which has been shown to maintain contractile force by associating with troponin I in myocytes. The effect of mTOR on the expression of both fetal and constitutive hypertrophy genes is not well understood. However, mTORC1 and 2 may contribute to the hypertrophic changes observed in the hypercholesterolemic myocardium.

Hypercholesterolemia is a prevalent condition in patients with ischemic heart disease, and influences outcomes after cardiac events and procedures. Previous studies have focused on microvascular endothelial dysfunction as an explanation for hypercholesterolemia’s adverse cardiac effects. However, metabolic conditions within myocytes influence the heart’s response to ischemic injury and are altered by major cardiovascular risk factors. The hypercholesterolemic pigs in our study exhibited a 45% greater infarct after ischemia-reperfusion than control pigs, after only four weeks of feeding with a hypercholesterolemic diet that also activated mTOR. Constitutive activation of mTOR has been shown both in vitro and in vivo to induce necrosis, apoptosis and autophagic cell death upon nutrient deprivation and hypoxia, and transgenic mice with chronic activation of Akt displayed a larger infarct after cardiac I/R. Our study is the first to suggest that hyperactivation of the mTOR pathway through dietary modifications in a large animal model may sensitize the myocardium to I/R injury.

Hyperactive mTOR signaling may increase myocardial susceptibility to ischemic injury in several ways (Fig. 8). Decreasing myocardial energy demand is a major strategy for reducing I/R injury during acute myocardial infarction. mTORC1 instead increases energy demand by activating translation and promoting the development of a hypertrophic, hypercontractile phenotype. In fact, inhibition of protein synthesis, in part through HIF-1α-mediated downregulation of mTOR signaling, has been shown to protect cells from hypoxia by reducing mTOR-mediated stimulation of translation. We observed a potential activation of translation in both the ischemic and non-ischemic myocardial territories of the HC group, including lower levels of HIF-1α, in conjunction with higher S6K1 levels, which activates the ribosomal protein S6, in the ischemic myocardial territory (Suppl. Fig. 3B). Similarly, these HC pigs demonstrated hyperdynamic cardiac function throughout the entire I/R event, including increased developed left ventricular pressure, peak systolic function, and mean arterial pressure (MAP). On a molecular level, the activation of mTORC1 in the HC group also inhibited autophagy, an important cellular process for degrading old organelles and proteins, as indicated by the lower ratio of LC3B-II/I, a marker of autophagy. Combined with increased protein synthesis, the activation of mTORC1 may have led not only to a hypertrophic, hyperdynamic phenotype, but also to the accumulation of misfolded proteins and damaged mitochondria in the HC myocardium, increasing its susceptibility to ischemia.

mTORC2 may also play a role in ischemic injury through its activation of PKCα and Akt. PKCα contributes to microvascular dysfunction and I/R injury, especially in the setting of hypercholesterolemia. Akt may also contribute to the metabolic effects of hypercholesterolemia on the myocardium, since it promotes the intracellular transport of glucose and lipids and further activates mTORC1. We hypothesize that this coactivation of cardiac mTORC1 and 2 perpetuates a hyperactive energy supply-demand cycle in the hypercholesterolemic myocardium, increasing its susceptibility to the withdrawal of nutrients and oxygen upon ischemia.

In conclusion, our study highlights a role for cardiac mTORC1 and 2 signaling in nutritional excess, hypercholesterolemia and ischemic injury. It cannot (1) refute the possibility that hemodynamic stress, due to a high MAP or the acute I/R event also activated mTOR signaling in the non-ischemic left ventricle; nor (2) provide direct evidence that hypercholesterolemia specifically activates mTORC1 in 2 in myocytes. Instead, we used a clinically-relevant porcine model of diet-induced hypercholesterolemia, which is known to produce multiple changes similar to the metabolic syndrome in humans. These pigs had slight hypertension, slight hypertriglyceridemia, and likely metabolic changes in other organs that may have also contributed to the alterations we observed in cardiac mTORC1 and 2 signaling. This is a strength and not a weakness of our study since it implicates hyperactive mTORC1 and 2 signaling in the cardiac pathologies associated with a high-fat/high-cholesterol diet, and correlates
novel changes in mTOR and raptor expression with cholesterol levels. Rapamycin, which dissociates mTOR from raptor and can inhibit both mTORC1 and 2, is already being used clinically in transplantation and drug-eluting stents. Given our findings, it is worth examining the potential utility of rapamycin as well as specific mTORC1 and 2 inhibitors in models of I/R, hypertrophy and heart failure, particularly in the setting of hypercholesterolemia and other metabolic diseases.

**Methods**

**Animals.** At 20 weeks of age, seven intact male Yucatan mini-pigs were fed a normal diet (NC) consisting of standard Minipig Breeder Diet (Purina, St. Louis, MO), while seven were fed a hypercholesterolemic diet (HC) for 4 weeks that substituted 25% of the ND with 17.2% coconut oil, 2.3% corn oil, 4% cholesterol and 1.5% sodium cholate. Animals were housed individually and provided with laboratory chow and water ad libitum. All experiments were approved by the Beth Israel Deaconess Medical Center Animal Care and Use Committee and the Harvard Medical Area Standing Committee on Animals. This investigation conforms with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

Pigs were fasted for 12 hours prior to harvesting the tissue used in this study. They had undergone 1 hr. myocardial ischemia/2 hr. reperfusion of the left anterior descending coronary artery for another study, and monastryl blue dye (Engelhard Corp., Louisville, KY) was injected into the coronary arteries to demarcate the non-ischemic ventricular tissue before harvesting. Only non-ischemic tissue was used in this study. Tissue was rapidly frozen in liquid nitrogen and stored at -80°C for use in western blotting. Tissue was fixed in 10% formaldehyde for 3 hours followed by 20% sucrose overnight at 4°C, mounted in tissue blocks with OCT (Sakura Finetek, Torrance, CA), and frozen at -80°C for use in immunofluorescence studies.

**Western blotting.** Ventricular tissue from the non-ischemic territory was homogenized in 25 mL RIPA buffer consisting of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (Boston Bioproducts, Worcester, MA), phosphatase inhibitor cocktails I and II at 1:100 (Sigma, St. Louis, MO), one-half tablet of Complete EDTA-free protease inhibitor cocktail (Roche, Indianapolis, IN) and 64 mM NaF (Fisher Scientific, Pittsburgh, PA). Protein concentration was quantified using the Micro BCA Protein Assay Kit (Pierce, Rockford, Illinois) and equal amounts of protein (35 to 40 μg) were subjected to SDS-PAGE on 4–20% polyacrylamide gels (Pierce, Rockford, Illinois). Proteins were transferred to PVDF membranes (Millipore, Bellerica, MA) at 40 V overnight. Membranes were stained with Ponceau S to ensure equal protein transfer and separation. Membranes were blocked in 5% blotting-grade milk (Biorad, Hercules, CA), washed in TBS with 0.05% Tween-20 (Boston Bioproducts), followed by incubations in primary and secondary antibodies and Supersignal West Pico Chemiluminescent Substrate (Pierce) according to the manufacturers’ recommendation.

Optical density values were obtained from X-ray films using a flat-bed scanner and ImageJ 1.4 software (National Institutes of...
Hypercholesterolemia activates cardiac mTOR signaling

Figure 7. Hypercholesterolemia is associated with increased levels of hypertrophy-associated proteins, and a trend toward decreased autophagy in the myocardium. Representative western blots for β-actin, troponin I, troponin T, SERCA2 ATPase, α-tubulin, LC3B-I&II and GAPDH as a loading control in the left ventricle of hypercholesterolemic (HC) and normocholesterolemic (NC) pigs, and quantification of the data. Bands were rearranged from the original gel for clarity of presentation. Densities were calculated relative to total Ponceau S staining. The ratio of LC3B-II to I (LC3B-II/Ir) was calculated by dividing the density of the bottom band by that of the top on the LC3B blots. Data are expressed as mean ± SEM. *p < 0.05 versus control.

Immunofluorescence. Three animals were analyzed randomly from each group. Ten μm frozen sections from the non-ischemic ventricular territory were washed in PBS for 5 min and treated with 1% SDS (Boston Bioproducts) for 5 min. Sections were washed 3 times before blocking in 1% BSA for 1 hr. An mTOR antibody (the same used in immunoblots) was added overnight at 4°C, followed by 3 washes in PBS and incubation with anti-rabbit AlexaFluor 555 (Molecular Probes, Eugene, OR) for 30 min. Slides were viewed again in three times in PBS and mounted in Vectashield plus DAPI (Vector Labs, Burlingame, CA). Slides were viewed under a Zeiss LSM510 confocal microscope (Carl Zeiss MicroImaging Inc., Thornwood, NY). Negative controls consisted of adsorption of the mTOR antibody with a blocking peptide or skipping the primary antibody. The images shown were taken at settings for which incubation with secondary antibody alone showed no signal.

Antibodies. All antibodies and blocking peptide were obtained from Cell Signaling Technology (Beverly, MA) with the following exceptions: anti-α-tubulin and anti-HIF-1α from Sigma (St. Louis, MO), anti-REDD1 from Proteintech Group, Inc. (Chicago, IL), anti-PKCα and anti-β-actin HRP from Santa Cruz Biotechnology (Santa Cruz, CA), anti-troponin I and anti-troponin T from US Biologicals (Swampscott, MA), and peroxidase-conjugated anti-rabbit light-chain specific secondary antibody from Jackson Immunoresearch (West Grove, PA) for phospho-S6K1 blots. The

Health, USA). All calculated densities were normalized to total Ponceau S staining intensity. Protein phosphorylation was assayed by dividing levels of the phosphorylated form of the protein by levels of its total expression. Expression levels are presented in arbitrary units as mean ± SEM. Samples were originally loaded in a different order, and bands from X-ray films were rearranged in the Figures for clarity of presentation.

Immunofluorescence. Three animals were analyzed randomly from each group. Ten μm frozen sections from the non-ischemic ventricular territory were washed in PBS for 5 min and treated with 1% SDS (Boston Bioproducts) for 5 min. Sections were washed 3 times before blocking in 1% BSA for 1 hr. An mTOR antibody (the same used in immunoblots) was added overnight at 4°C, followed by 3 washes in PBS and incubation with anti-rabbit AlexaFluor 555 (Molecular Probes, Eugene, OR) for 30 min. Sections were washed again in three times in PBS and mounted in Vectashield plus DAPI (Vector Labs, Burlingame, CA). Slides were viewed under a Zeiss LSM510 confocal microscope (Carl Zeiss MicroImaging Inc., Thornwood, NY). Negative controls consisted of adsorption of the mTOR antibody with a blocking peptide or skipping the primary antibody. The images shown were taken
phospho-pan PKC antibody was #9371 from Cell Signaling.

Statistical analysis. Densitometry values were analyzed with the unpaired student’s t-test or Mann-Whitney U test when appropriate (SigmapStat, Systat Software, San Jose, CA), and Pearson or Spearman’s correlation coefficients with respective p values were calculated using GraphPad Prism 4 (GraphPad Software, La Jolla, CA). One control animal was excluded from the study using Dixon’s Q-test due to extremely high phosphorylation and total levels of many proteins measured in this study.

Acknowledgements

We thank the staff of the Animal Research Facility at the Beth Israel Deaconess Medical Center for their work. We also thank Dr. John Blenis for his critical reading of the manuscript.

This work was supported by the National Heart, Lung and Blood Institute [HL46716 and HL69024 to F.W.S.]; the Jack Kent Cook Foundation [to H.P.G.]; and the National Institutes of Health [HL076130 to R.M.O.].

Note

Supplementary materials can be found at: www.landesbioscience.com/supplement/glazercc8-11-sup.pdf

References


www.landesbioscience.com Cell Cycle 1745
Hypercholesterolemia activates cardiac mTOR signaling


